{"id":16341,"date":"2022-09-30T10:52:14","date_gmt":"2022-09-30T09:52:14","guid":{"rendered":"https:\/\/touchrespiratory.com\/?post_type=media_gallery&p=16341"},"modified":"2022-09-30T11:02:03","modified_gmt":"2022-09-30T10:02:03","slug":"robin-deterding-ers-2022-nintedanib-for-children-and-adolescents-with-fibrosing-interstitial-lung-diseases","status":"publish","type":"media_gallery","link":"https:\/\/touchrespiratory.com\/interstitial-lung-disease\/conference-hub\/robin-deterding-ers-2022-nintedanib-for-children-and-adolescents-with-fibrosing-interstitial-lung-diseases\/","title":{"rendered":"Robin Deterding, ERS 2022: Nintedanib for Children and Adolescents with Fibrosing Interstitial Lung Diseases"},"content":{"rendered":"
Nintedanib is an inhibitor of tyrosine kinases involved in the progression of pulmonary fibrosis and blocks the signalling pathways involved in fibrotic processes. We were delighted to speak to Dr. Robin Deterding<\/strong> (University of Colorado; Children’s Hospital Colorado, Aurora, CO, USA) around the incidence, prognosis and unmet needs in the treatment of childhood interstitial lung disease and the evidence supporting the investigation of nintedanib in this indication.<\/p>\n